Ranjan Ray, MD
Advanced Heart Failure and Transplant Cardiology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Office
- 1
- Since medical school
- 20 years
- Graduated 2006
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Alta Bates Summit Medical Center · California Pacific Medical Center- Van Ness Campus · Novato Community Hospital · Sutter Medical Center, Sacramento · Sutter Santa Rosa Regional Hospital. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ray’s office at (415) 600-1020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A108532 · Current
Licensed to practise in California · since 2009 · expires 2027-06-30 · Georgetown University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Advanced Heart Failure and Transplant
- American Board of Internal Medicine - Cardiovascular Disease
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- Novato Community HospitalNovato, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Sutter Medical Center, SacramentoSacramento, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.9 (12 to 15.9) · 992 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.066, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.335, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.215, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.46, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.253, Oct 2024 – Sep 2025
- Sutter Santa Rosa Regional HospitalSanta Rosa, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.157, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Novato Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 213 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.4 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 25 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 627 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,872 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,796 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.92 (0.5 to 5.33) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 317 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.2 (0.51 to 3.88) · 495 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.93 (0 to 17.29) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 311 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,320 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 143 cases | None | Apr 2023 – Mar 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 108 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.9 · 121 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.1 · 150 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 118 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 930 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 184 cases | No different | Jan 2024 – Dec 2024 |
What patients said (334 patients answered, 30% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sutter Medical Center, Sacramento
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.9 (12 to 15.9) · 992 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.066 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.335 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.215 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.46 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.253 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.12 (0.29 to 1.94) · 2,408 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.78 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.68 (126.66 to 206.71) · 180 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 292 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.8 · 543 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 425 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 5,216 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.11 (0 to 0.29) · 9,948 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.45) · 10,968 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.04 (1.53 to 4.56) · 3,983 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.33 (0.2 to 2.46) · 2,033 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.78 (1.69 to 3.87) · 3,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.79 (6.29 to 13.29) · 2,100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.62 (4.04 to 9.2) · 2,018 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.29 to 2.98) · 867 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.54 (0.07 to 1.01) · 8,613 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 294 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 598 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 924 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.5 · 488 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18.3 · 638 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.4 · 443 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 600 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.9 to 6.1) · 992 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 298 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 249 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.7 to 14.6) · 1,326 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 934 cases | No different | Jan 2024 – Dec 2024 |
What patients said (700 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Sutter Santa Rosa Regional Hospital
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.157 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.03 (0.08 to 1.99) · 1,147 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.03 (0.69 to 1.37) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 162.53 (108.3 to 216.76) · 54 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 316 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14 · 296 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 142 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,971 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.06 to 0.47) · 4,946 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.43) · 4,974 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.99 (2.93 to 7.06) · 1,288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0 to 3.15) · 532 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (0.82 to 3.9) · 1,214 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.87 (2.35 to 17.39) · 558 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.01 (4.29 to 11.73) · 522 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.6 (0.14 to 3.05) · 337 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.18 (0 to 0.89) · 4,064 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 206 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.626 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.299 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 342 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -4.1 · 184 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -14 · 352 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -17.4 · 309 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.2 · 309 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.2 (5.1 to 9.8) · 259 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.6 (8.8 to 15) · 259 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 215 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 100 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.8 to 18) · 1,275 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 702 cases | No different | Jan 2024 – Dec 2024 |
What patients said (752 patients answered, 22% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$199,360
Medicare paid this office $199,360 for 369 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 36 | $80,616 | $185 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $29,013 | $106 |
| Long return visit (40+ min) | 94 | $20,221 | $124 |
| Return visit (30+ min) | 61 | $13,534 | $108 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 112 | $12,864 | $100 |
See all 14 services
| Critical care, first 30-74 minutes | 36 | $80,616 | $185 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $29,013 | $106 |
| Long return visit (40+ min) | 94 | $20,221 | $124 |
| Return visit (30+ min) | 61 | $13,534 | $108 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 112 | $12,864 | $100 |
| Evaluation of lower heart chamber assist device | 50 | $9,938 | $34 |
| Return visit (30+ min) | 51 | $8,997 | $77 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 63 | $4,582 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,396 | $152 |
| New patient visit (60+ min) | 16 | $3,328 | $208 |
| New patient visit (60+ min) | 14 | $2,096 | $150 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 97 | $1,265 | $13 |
| Ultrasound of heart, follow-up | 13 | $308 | $22 |
| 3d radiographic procedure | 11 | $84 | $8 |
Who their Medicare patients are
369 Original Medicare patients in 2024. Average age 74 · Under 65 8% · 85 and older 11% · Women 44% · Also on Medicaid 20% · Health risk score 1.91. At or below the middle of the specialty; the typical advanced heart failure and transplant cardiology clinician is at 2.53.
Conditions among them: High blood pressure 75% · Heart failure 51% · Coronary heart disease 44% · Chronic kidney disease 42% · Atrial fibrillation 37% · Diabetes 31% · Depression 21% · Cancer 15% · COPD 14% · Stroke 8% · Dementia 7%.
The office billed $948,428, Medicare allowed $258,792 and paid $199,360; for 1,938 services of 39 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 369 | 1,938 | 74 | 1.91 | $948,428 | $199,360 |
| 2023 | 367 | 1,661 | 73 | 2.10 | $746,453 | $168,211 |
| 2022 | 335 | 1,627 | 73 | 2.07 | $667,637 | $157,121 |
| 2021 | 316 | 1,607 | 73 | 2.12 | $681,415 | $165,264 |
| 2020 | 284 | 1,123 | 72 | 2.37 | $444,918 | $111,410 |
| 2019 | 182 | 1,249 | 69 | 3.08 | $545,131 | $132,418 |
| 2018 | 164 | 1,027 | 69 | 3.29 | $416,410 | $103,883 |
| 2017 | 261 | 1,154 | 70 | 2.56 | $438,318 | $111,029 |
| 2016 | 708 | 1,216 | 71 | 2.44 | $218,254 | $50,332 |
| 2015 | 850 | 1,474 | 72 | 2.17 | $216,161 | $50,658 |
| 2014 | 1,438 | 2,298 | 72 | 2.01 | $220,367 | $45,782 |
| 2013 | 383 | 572 | 72 | 2.14 | $63,994 | $13,958 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Critical care, first 30-74 minutes | 43 | $57,364 | $189 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $27,682 | $106 |
| Long return visit (40+ min) | 91 | $19,956 | $126 |
| Return visit (30+ min) | 61 | $14,087 | $109 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 86 | $9,635 | $99 |
| Evaluation of lower heart chamber assist device | 49 | $9,612 | $35 |
| Return visit (30+ min) | 54 | $7,701 | $77 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,311 | $149 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 55 | $3,987 | $61 |
| New patient visit (60+ min) | 15 | $2,886 | $192 |
| New patient visit (60+ min) | 16 | $2,629 | $164 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 98 | $1,205 | $12 |
| 3d radiographic procedure | 16 | $138 | $8 |
2022: 13 services
| Critical care, first 30-74 minutes | 40 | $40,331 | $193 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $31,612 | $92 |
| Long return visit (40+ min) | 96 | $23,506 | $127 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 96 | $11,433 | $91 |
| Return visit (30+ min) | 53 | $9,876 | $85 |
| Return visit (30+ min) | 41 | $9,611 | $108 |
| Evaluation of lower heart chamber assist device | 44 | $8,261 | $35 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,134 | $177 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 44 | $3,050 | $64 |
| Long return visit (40+ min) | 13 | $2,753 | $162 |
| New patient visit (60+ min) | 13 | $2,149 | $165 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 86 | $1,115 | $12 |
| 3d radiographic procedure | 21 | $421 | $17 |
2021: 11 services
| Critical care, first 30-74 minutes | 46 | $51,175 | $193 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $29,503 | $93 |
| Long return visit (40+ min) | 88 | $22,946 | $126 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 95 | $11,951 | $102 |
| Return visit (30+ min) | 43 | $10,209 | $86 |
| Return visit (30+ min) | 37 | $9,621 | $113 |
| Evaluation of lower heart chamber assist device | 31 | $7,196 | $34 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $6,494 | $180 |
| Long return visit (40+ min) | 13 | $3,559 | $148 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 45 | $3,368 | $62 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 86 | $1,046 | $12 |
2020: 10 services
| Critical care, first 30-74 minutes | 37 | $38,754 | $202 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $16,414 | $95 |
| Long return visit (40+ min) | 64 | $14,773 | $97 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 70 | $9,437 | $114 |
| Evaluation of lower heart chamber assist device | 34 | $7,358 | $43 |
| Return visit (30+ min) | 27 | $4,808 | $91 |
| Return visit (30+ min) | 29 | $4,157 | $68 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,523 | $185 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 29 | $2,388 | $68 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 93 | $1,376 | $14 |
2019: 9 services
| Critical care, first 30-74 minutes | 48 | $54,221 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $21,460 | $94 |
| Long return visit (40+ min) | 87 | $21,175 | $95 |
| Evaluation of lower heart chamber assist device | 31 | $9,007 | $41 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 75 | $6,851 | $66 |
| Return visit (30+ min) | 24 | $5,023 | $98 |
| Long return visit (40+ min) | 22 | $4,369 | $125 |
| Return visit (30+ min) | 21 | $3,174 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,858 | $169 |
2018: 9 services
| Critical care, first 30-74 minutes | 33 | $32,963 | $194 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $18,528 | $93 |
| Long return visit (40+ min) | 76 | $17,898 | $91 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 69 | $7,072 | $64 |
| Evaluation of lower heart chamber assist device | 24 | $6,700 | $40 |
| Return visit (30+ min) | 26 | $4,958 | $92 |
| Long return visit (40+ min) | 20 | $4,315 | $135 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,421 | $180 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 11 | $2,664 | $205 |
2017: 9 services
| Critical care, first 30-74 minutes | 33 | $45,277 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $21,085 | $93 |
| Long return visit (40+ min) | 65 | $13,772 | $94 |
| Evaluation of lower heart chamber assist device | 19 | $7,422 | $41 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,247 | $181 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 52 | $4,433 | $58 |
| Return visit (30+ min) | 19 | $4,137 | $94 |
| Return visit (30+ min) | 24 | $2,736 | $65 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 108 | $863 | $8 |
2016: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $29,184 | $92 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 610 | $5,144 | $7 |
| Long return visit (40+ min) | 48 | $4,742 | $97 |
| Return visit (30+ min) | 15 | $3,184 | $88 |
| Return visit (30+ min) | 35 | $3,153 | $67 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,306 | $177 |
| Hospital discharge day management, 30 minutes or less | 12 | $855 | $66 |
2015: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $24,644 | $92 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 757 | $7,652 | $8 |
| Return visit (30+ min) | 42 | $4,379 | $68 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $3,077 | $181 |
| Long return visit (40+ min) | 30 | $2,979 | $99 |
| Return visit (30+ min) | 17 | $2,732 | $94 |
| New patient visit (60+ min) | 13 | $2,253 | $173 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,260 | $66 |
2014: 7 services
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 1,355 | $14,554 | $7 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $13,130 | $91 |
| New patient visit (60+ min) | 20 | $3,618 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $3,074 | $64 |
| Return visit (30+ min) | 28 | $2,937 | $70 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,910 | $171 |
| Long return visit (40+ min) | 30 | $2,862 | $95 |
2013: 3 services
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 335 | $3,349 | $7 |
| New patient visit (60+ min) | 14 | $2,499 | $178 |
| Long return visit (40+ min) | 14 | $1,335 | $95 |
Medicaid work
$2,422 in 2024
Medicaid paid $2,422 for 37 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 37 | $2,422 |
| 2024 | 37 | 1 | 13 | $2,422 |
| 2023 | 66 | 1 | 18 | $5,506 |
| 2022 | 29 | 2 | 14 | $1,715 |
| 2021 | 41 | 1 | 13 | $4,317 |
| 2020 | 17 | 1 | 16 | $1,786 |
| 2019 | 26 | 2 | 13 | $1,521 |
| 2018 | 86 | 1 | 18 | $6,669 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 66 | $5,506 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 15 | $1,344 |
| Return visit (30+ min) | 14 | $371 |
2021
| Long return visit (40+ min) | 41 | $4,317 |
2020
| Long return visit (40+ min) | 17 | $1,786 |
2019
| Interrogation of ventricular assist device (VAD), in person, with physician or other qualified health care professional analysis of device parameters (eg, drivelines, alarms, power surges), review of device function (eg, flow and volume status, septum status, recovery), with programming, if performed, and report | 13 | $831 |
| Long return visit (40+ min) | 13 | $690 |
2018
| Long return visit (40+ min) | 86 | $6,669 |
Drugs they prescribed that Part D paid
$1,412,600
Pharmacies billed $1,412,600 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,697) in 2024. At or below the middle of the specialty; the typical advanced heart failure and transplant cardiology clinician is at 0%.
1,337 generic and 360 brand-name prescriptions · $1,412,600 in drug cost · 18 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vyndamax | 43 | $1,029,711 | $23,947 |
| Eliquis | 96 | $82,515 | $860 |
| Entresto | 62 | $80,041 | $1,291 |
| Farxiga | 41 | $56,649 | $1,382 |
| Jardiance | 40 | $52,462 | $1,312 |
See all 31 drugs
| Vyndamax | 43 | $1,029,711 | $23,947 |
| Eliquis | 96 | $82,515 | $860 |
| Entresto | 62 | $80,041 | $1,291 |
| Farxiga | 41 | $56,649 | $1,382 |
| Jardiance | 40 | $52,462 | $1,312 |
| Tacrolimus | 39 | $9,387 | $241 |
| Repatha | 12 | $6,539 | $545 |
| Bumetanide | 47 | $2,271 | $48 |
| Mycophenolate Mofetil | 13 | $1,595 | $123 |
| Rosuvastatin | 59 | $1,460 | $25 |
| Losartan | 128 | $1,430 | $11 |
| Atorvastatin | 121 | $1,085 | $9 |
| Metoprolol | 53 | $937 | $18 |
| Potassium Chloride | 35 | $931 | $27 |
| Carvedilol | 82 | $898 | $11 |
| Isosorbide Mononitrate Er | 26 | $887 | $34 |
| Pantoprazole | 65 | $870 | $13 |
| Lisinopril | 68 | $699 | $10 |
| Warfarin | 36 | $692 | $19 |
| Spironolactone | 63 | $687 | $11 |
| Pravastatin | 37 | $632 | $17 |
| Amlodipine Besylate | 110 | $626 | $6 |
| Hydralazine | 27 | $623 | $23 |
| Torsemide | 11 | $465 | $42 |
| Ezetimibe | 18 | $443 | $25 |
| Furosemide | 73 | $433 | $6 |
| Levothyroxine | 17 | $258 | $15 |
| Valsartan | 11 | $231 | $21 |
| Prednisone | 14 | $90 | $6 |
| Clonidine | 11 | $58 | $5 |
| Hydrochlorothiazide | 14 | $47 | $3 |
Year by year
| 2024 | 1,697 | 222 | 0% (0) | 21% | $1,412,600 |
| 2023 | 1,600 | 197 | 0% (0) | 19% | $717,649 |
| 2022 | 1,051 | 169 | 0% (0) | 13% | $461,481 |
| 2021 | 1,091 | 145 | 0% (0) | None | $300,754 |
| 2020 | 1,135 | 119 | None | None | $168,567 |
| 2019 | 1,099 | 106 | 0% (0) | 11% | $203,332 |
| 2018 | 868 | 104 | 0% (0) | 11% | $75,844 |
| 2017 | 1,562 | 164 | 0% (0) | None | $241,171 |
| 2016 | 1,825 | 138 | None | 15% | $249,393 |
| 2015 | 1,529 | 125 | 0% (0) | None | $226,016 |
| 2014 | 1,013 | 86 | None | None | $177,550 |
| 2013 | 227 | 49 | None | None | $35,221 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 30 drugs
| Vyndamax | 15 | $325,801 | $21,720 |
| Eliquis | 72 | $63,962 | $888 |
| Entresto | 44 | $55,868 | $1,270 |
| Farxiga | 47 | $52,699 | $1,121 |
| Jardiance | 35 | $32,303 | $923 |
| Repatha Sureclick | 18 | $10,916 | $606 |
| Everolimus | 13 | $10,093 | $776 |
| Praluent | 12 | $6,280 | $523 |
| Tacrolimus | 18 | $4,664 | $259 |
| Bumetanide | 55 | $3,314 | $60 |
| Potassium Chloride | 48 | $2,729 | $57 |
| Losartan | 112 | $2,509 | $22 |
| Rosuvastatin | 45 | $2,133 | $47 |
| Pantoprazole | 57 | $1,804 | $32 |
| Warfarin | 90 | $1,592 | $18 |
| Atorvastatin | 96 | $1,590 | $17 |
| Metoprolol | 56 | $1,425 | $25 |
| Hydralazine | 33 | $1,210 | $37 |
| Amlodipine Besylate | 101 | $1,194 | $12 |
| Carvedilol | 70 | $1,188 | $17 |
| Lisinopril | 64 | $1,182 | $18 |
| Pravastatin | 48 | $993 | $21 |
| Ezetimibe | 20 | $835 | $42 |
| Isosorbide Mononitrate Er | 20 | $593 | $30 |
| Furosemide | 68 | $542 | $8 |
| Spironolactone | 39 | $480 | $12 |
| Amiodarone | 12 | $467 | $39 |
| Valsartan | 15 | $323 | $22 |
| Levothyroxine | 16 | $322 | $20 |
| Hydrochlorothiazide | 19 | $132 | $7 |
2022: 26 drugs
| Vyndamax | 14 | $301,739 | $21,553 |
| Entresto | 22 | $27,291 | $1,241 |
| Eliquis | 32 | $26,571 | $830 |
| Farxiga | 14 | $16,404 | $1,172 |
| Mycophenolic Acid | 12 | $9,834 | $820 |
| Tacrolimus | 26 | $6,288 | $242 |
| Rosuvastatin | 50 | $2,501 | $50 |
| Bumetanide | 27 | $2,417 | $90 |
| Hydralazine | 70 | $2,125 | $30 |
| Pravastatin | 62 | $1,360 | $22 |
| Lisinopril | 54 | $1,151 | $21 |
| Losartan | 53 | $1,133 | $21 |
| Pantoprazole | 38 | $916 | $24 |
| Amlodipine Besylate | 76 | $880 | $12 |
| Warfarin | 49 | $856 | $17 |
| Carvedilol | 51 | $853 | $17 |
| Potassium Chloride | 26 | $676 | $26 |
| Atorvastatin | 47 | $572 | $12 |
| Isosorbide Mononitrate Er | 15 | $413 | $28 |
| Metoprolol | 16 | $307 | $19 |
| Amiodarone | 14 | $274 | $20 |
| Furosemide | 31 | $255 | $8 |
| Levothyroxine | 11 | $247 | $22 |
| Prednisone | 19 | $245 | $13 |
| Spironolactone | 15 | $206 | $14 |
| Clopidogrel | 13 | $184 | $14 |
2021: 26 drugs
| Entresto | 27 | $21,820 | $808 |
| Eliquis | 21 | $19,402 | $924 |
| Mycophenolic Acid | 12 | $9,871 | $823 |
| Tacrolimus | 20 | $3,863 | $193 |
| Bumetanide | 43 | $2,906 | $68 |
| Mycophenolate Mofetil | 16 | $2,229 | $139 |
| Rosuvastatin | 36 | $1,508 | $42 |
| Doxycycline Hyclate | 15 | $1,239 | $83 |
| Warfarin | 77 | $1,129 | $15 |
| Potassium Chloride | 40 | $1,112 | $28 |
| Hydralazine | 49 | $1,104 | $23 |
| Losartan | 59 | $1,034 | $18 |
| Pantoprazole | 28 | $743 | $27 |
| Carvedilol | 49 | $685 | $14 |
| Omega-3 Acid Ethyl Esters | 11 | $678 | $62 |
| Lisinopril | 83 | $644 | $8 |
| Pravastatin | 48 | $560 | $12 |
| Furosemide | 29 | $479 | $17 |
| Amlodipine Besylate | 55 | $436 | $8 |
| Atorvastatin | 53 | $379 | $7 |
| Prednisone | 31 | $310 | $10 |
| Gabapentin | 19 | $225 | $12 |
| Spironolactone | 21 | $190 | $9 |
| Isosorbide Mononitrate Er | 11 | $94 | $9 |
| Sulfamethoxazole-Trimethoprim | 13 | $87 | $7 |
| Glipizide | 11 | $32 | $3 |
2020: 26 drugs
| Entresto | 13 | $14,484 | $1,114 |
| Tacrolimus | 48 | $10,003 | $208 |
| Mycophenolic Acid | 12 | $8,746 | $729 |
| Mycophenolate Mofetil | 32 | $3,835 | $120 |
| Bumetanide | 36 | $2,687 | $75 |
| Warfarin | 124 | $2,108 | $17 |
| Potassium Chloride | 57 | $1,635 | $29 |
| Colchicine | 11 | $1,565 | $142 |
| Pantoprazole | 60 | $1,539 | $26 |
| Lisinopril | 87 | $946 | $11 |
| Pravastatin | 45 | $828 | $18 |
| Atorvastatin | 55 | $693 | $13 |
| Prednisone | 38 | $584 | $15 |
| Losartan | 33 | $580 | $18 |
| Hydralazine | 23 | $578 | $25 |
| Isosorbide Mononitrate Er | 16 | $536 | $33 |
| Furosemide | 53 | $500 | $9 |
| Doxycycline Hyclate | 13 | $448 | $34 |
| Levothyroxine | 18 | $377 | $21 |
| Rosuvastatin | 18 | $344 | $19 |
| Carvedilol | 39 | $270 | $7 |
| Amlodipine Besylate | 44 | $260 | $6 |
| Sulfamethoxazole-Trimethoprim | 32 | $242 | $8 |
| Gabapentin | 16 | $197 | $12 |
| Spironolactone | 20 | $187 | $9 |
| Clopidogrel | 12 | $97 | $8 |
2019: 26 drugs
| Entresto | 22 | $12,297 | $559 |
| Tacrolimus | 29 | $6,122 | $211 |
| Omega-3 Acid Ethyl Esters | 16 | $3,721 | $233 |
| Colchicine | 13 | $2,277 | $175 |
| Warfarin | 104 | $2,274 | $22 |
| Mycophenolate Mofetil | 25 | $2,231 | $89 |
| Clotrimazole | 11 | $1,943 | $177 |
| Atorvastatin | 39 | $1,251 | $32 |
| Bumetanide | 16 | $1,211 | $76 |
| Pravastatin | 92 | $1,146 | $12 |
| Nystatin | 18 | $1,116 | $62 |
| Hydralazine | 49 | $1,040 | $21 |
| Potassium Chloride | 27 | $978 | $36 |
| Rosuvastatin | 21 | $925 | $44 |
| Prednisone | 62 | $710 | $11 |
| Lisinopril | 68 | $614 | $9 |
| Furosemide | 62 | $612 | $10 |
| Pantoprazole | 47 | $599 | $13 |
| Losartan | 42 | $488 | $12 |
| Amlodipine Besylate | 47 | $375 | $8 |
| Gabapentin | 15 | $196 | $13 |
| Amiodarone | 16 | $183 | $11 |
| Sulfamethoxazole-Trimethoprim | 19 | $160 | $8 |
| Carvedilol | 28 | $157 | $6 |
| Spironolactone | 18 | $147 | $8 |
| Glipizide Er | 14 | $97 | $7 |
2018: 23 drugs
| Valganciclovir | 14 | $13,619 | $973 |
| Atovaquone | 11 | $10,736 | $976 |
| Potassium Chloride | 26 | $4,180 | $161 |
| Tacrolimus | 46 | $4,158 | $90 |
| Mycophenolate Mofetil | 25 | $2,387 | $95 |
| Bumetanide | 29 | $2,092 | $72 |
| Warfarin | 94 | $1,905 | $20 |
| Doxycycline Hyclate | 15 | $891 | $59 |
| Pravastatin | 74 | $862 | $12 |
| Nystatin | 22 | $702 | $32 |
| Atorvastatin | 29 | $507 | $17 |
| Losartan | 27 | $372 | $14 |
| Hydralazine | 11 | $339 | $31 |
| Prednisone | 29 | $302 | $10 |
| Furosemide | 36 | $240 | $7 |
| Carvedilol | 44 | $225 | $5 |
| Lisinopril | 32 | $198 | $6 |
| Levothyroxine | 11 | $182 | $17 |
| Amlodipine Besylate | 37 | $160 | $4 |
| Spironolactone | 18 | $154 | $9 |
| Sulfamethoxazole-Trimethoprim | 19 | $91 | $5 |
| Hydrochlorothiazide | 14 | $32 | $2 |
| Amoxicillin | 14 | $30 | $2 |
2017: 41 drugs
| Valganciclovir | 30 | $63,185 | $2,106 |
| Zortress | 11 | $32,616 | $2,965 |
| Sirolimus | 51 | $26,061 | $511 |
| Tacrolimus | 87 | $12,687 | $146 |
| Renvela | 12 | $6,056 | $505 |
| Zetia | 17 | $5,336 | $314 |
| Omega-3 Acid Ethyl Esters | 47 | $5,046 | $107 |
| Mycophenolate Mofetil | 59 | $4,217 | $71 |
| Nexium | 12 | $3,014 | $251 |
| Clotrimazole | 15 | $2,164 | $144 |
| Diltiazem 24hr Er | 30 | $2,137 | $71 |
| Potassium Chloride | 48 | $2,110 | $44 |
| Bumetanide | 37 | $1,330 | $36 |
| Pravastatin | 68 | $938 | $14 |
| Rosuvastatin | 22 | $686 | $31 |
| Lisinopril | 88 | $571 | $6 |
| Atorvastatin | 28 | $552 | $20 |
| Hydralazine | 28 | $513 | $18 |
| Pantoprazole | 48 | $511 | $11 |
| Warfarin | 29 | $447 | $15 |
| Levothyroxine | 48 | $439 | $9 |
| Chlorthalidone | 14 | $345 | $25 |
| Carvedilol | 30 | $327 | $11 |
| Clonidine | 30 | $305 | $10 |
| Amlodipine Besylate | 56 | $280 | $5 |
| Furosemide | 44 | $259 | $6 |
| Tamsulosin | 29 | $230 | $8 |
| Sulfamethoxazole-Trimethoprim | 33 | $221 | $7 |
| Clopidogrel | 14 | $218 | $16 |
| Famotidine | 46 | $200 | $4 |
| Prednisone | 32 | $198 | $6 |
| Omeprazole | 11 | $190 | $17 |
| Isosorbide Mononitrate Er | 15 | $181 | $12 |
| Spironolactone | 18 | $157 | $9 |
| Sertraline | 20 | $142 | $7 |
| Allopurinol | 13 | $131 | $10 |
| Losartan | 12 | $131 | $11 |
| Gabapentin | 11 | $84 | $8 |
| Glipizide | 12 | $60 | $5 |
| Hydrochlorothiazide | 23 | $47 | $2 |
| Alendronate | 11 | $38 | $3 |
2016: 42 drugs
| Sirolimus | 57 | $19,325 | $339 |
| Tacrolimus | 102 | $9,886 | $97 |
| Crestor | 32 | $7,372 | $230 |
| Mycophenolate Mofetil | 71 | $5,290 | $75 |
| Zetia | 12 | $3,320 | $277 |
| Potassium Chloride | 53 | $2,310 | $44 |
| Pravastatin | 99 | $1,503 | $15 |
| Hydralazine | 47 | $972 | $21 |
| Bumetanide | 31 | $917 | $30 |
| Bd Ultra-Fine Pen Needle | 12 | $885 | $74 |
| Levothyroxine | 31 | $663 | $21 |
| Carvedilol | 44 | $615 | $14 |
| Atorvastatin | 30 | $590 | $20 |
| Pantoprazole | 71 | $586 | $8 |
| Lisinopril | 79 | $577 | $7 |
| Diltiazem 24hr Cd | 19 | $573 | $30 |
| Metoprolol | 14 | $507 | $36 |
| Sulfamethoxazole-Trimethoprim | 47 | $433 | $9 |
| Clonidine | 41 | $425 | $10 |
| Mirtazapine | 13 | $414 | $32 |
| Famotidine | 42 | $404 | $10 |
| Torsemide | 18 | $338 | $19 |
| Doxepin | 15 | $323 | $22 |
| Klor-Con 10 | 13 | $311 | $24 |
| Amlodipine Besylate | 65 | $295 | $5 |
| Furosemide | 36 | $286 | $8 |
| Allopurinol | 19 | $275 | $14 |
| Prednisone | 37 | $208 | $6 |
| Losartan | 11 | $204 | $19 |
| Isosorbide Mononitrate Er | 22 | $194 | $9 |
| Clopidogrel | 27 | $174 | $6 |
| Tamsulosin | 15 | $173 | $12 |
| Spironolactone | 26 | $159 | $6 |
| Gabapentin | 25 | $155 | $6 |
| Alendronate | 38 | $150 | $4 |
| Sertraline | 31 | $149 | $5 |
| Hydrochlorothiazide | 42 | $141 | $3 |
| Acyclovir | 12 | $123 | $10 |
| Ranitidine | 18 | $116 | $6 |
| Ramipril | 22 | $93 | $4 |
| Glipizide | 16 | $33 | $2 |
| Atenolol | 12 | $19 | $2 |
2015: 43 drugs
| Valganciclovir | 24 | $47,258 | $1,969 |
| Atovaquone | 22 | $33,161 | $1,507 |
| Sirolimus | 69 | $30,357 | $440 |
| Zortress | 19 | $20,836 | $1,097 |
| Crestor | 32 | $7,948 | $248 |
| Tacrolimus | 58 | $4,395 | $76 |
| Mycophenolate Mofetil | 32 | $3,593 | $112 |
| Gengraf | 19 | $2,995 | $158 |
| Zetia | 11 | $2,576 | $234 |
| Pravastatin | 87 | $2,159 | $25 |
| Cyclosporine Modified | 11 | $1,834 | $167 |
| Clotrimazole | 15 | $1,205 | $80 |
| Potassium Chloride | 33 | $960 | $29 |
| Atorvastatin | 54 | $816 | $15 |
| Diltiazem 24hr Cd | 28 | $756 | $27 |
| Pantoprazole | 79 | $683 | $9 |
| Isosorbide Mononitrate Er | 31 | $475 | $15 |
| Sulfamethoxazole-Trimethoprim | 37 | $469 | $13 |
| Triamcinolone Acetonide | 14 | $463 | $33 |
| Levothyroxine | 23 | $399 | $17 |
| Hydralazine | 26 | $385 | $15 |
| Prednisone | 18 | $320 | $18 |
| Famotidine | 34 | $312 | $9 |
| Calcitriol | 11 | $296 | $27 |
| Carvedilol | 47 | $273 | $6 |
| Alendronate | 44 | $253 | $6 |
| Flecainide Acetate | 14 | $243 | $17 |
| Lisinopril | 37 | $240 | $6 |
| Doxepin | 12 | $221 | $18 |
| Clopidogrel | 26 | $220 | $8 |
| Hydrochlorothiazide | 39 | $216 | $6 |
| Furosemide | 40 | $201 | $5 |
| Amlodipine Besylate | 27 | $193 | $7 |
| Clonidine | 31 | $187 | $6 |
| Bupropion Hcl Sr | 21 | $178 | $8 |
| Allopurinol | 17 | $167 | $10 |
| Ranitidine | 21 | $143 | $7 |
| Omeprazole | 12 | $116 | $10 |
| Spironolactone | 23 | $97 | $4 |
| Citalopram Hbr | 14 | $74 | $5 |
| Glipizide | 24 | $63 | $3 |
| Trazodone | 12 | $56 | $5 |
| Zolpidem | 17 | $54 | $3 |
2014: 31 drugs
| Valcyte | 19 | $68,546 | $3,608 |
| Mepron | 12 | $17,146 | $1,429 |
| Rapamune | 16 | $10,582 | $661 |
| Tacrolimus | 41 | $6,163 | $150 |
| Humalog | 17 | $6,158 | $362 |
| Spiriva | 13 | $3,763 | $289 |
| Mycophenolate Mofetil | 15 | $2,247 | $150 |
| Pravastatin | 82 | $1,949 | $24 |
| Potassium Chloride | 53 | $948 | $18 |
| Clotrimazole | 18 | $754 | $42 |
| Atorvastatin | 49 | $743 | $15 |
| Sulfamethoxazole-Trimethoprim | 44 | $510 | $12 |
| Gabapentin | 30 | $500 | $17 |
| Carvedilol | 51 | $499 | $10 |
| Pantoprazole | 19 | $389 | $20 |
| Clopidogrel | 32 | $339 | $11 |
| Omeprazole | 18 | $290 | $16 |
| Alendronate | 24 | $273 | $11 |
| Hydralazine | 12 | $247 | $21 |
| Prednisone | 26 | $233 | $9 |
| Isosorbide Mononitrate Er | 21 | $180 | $9 |
| Clonidine | 25 | $157 | $6 |
| Famotidine | 20 | $149 | $7 |
| Simvastatin | 12 | $135 | $11 |
| Levothyroxine | 12 | $134 | $11 |
| Furosemide | 16 | $117 | $7 |
| Amlodipine Besylate | 20 | $116 | $6 |
| Allopurinol | 14 | $99 | $7 |
| Ranitidine | 12 | $82 | $7 |
| Lisinopril | 13 | $77 | $6 |
| Glipizide | 21 | $76 | $4 |
2013: 3 drugs
| Mepron | 13 | $18,289 | $1,407 |
| Pravastatin | 16 | $278 | $17 |
| Carvedilol | 12 | $138 | $11 |
Money from drug and device companies
$323 in 2025
| 2025 | 7 | 8 | None | $323 |
| 2024 | 7 | 9 | None | $479 |
| 2023 | 1 | 2 | None | $54 |
| 2022 | 1 | 2 | None | $75 |
| 2021 | 6 | 11 | None | $340 |
| 2020 | 8 | 14 | None | $359 |
| 2019 | 11 | 30 | $24 | $1,068 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abiomed | None | $123 | 1 payment
|
| Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor | $44 | 2 payments
|
| Paragonix Technologies | Sherpapak | $44 | 1 payment
|
| Pfizer | Vyndaqel | $31 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $28 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $27 | 1 payment
|
See all 8 published payments
| Abiomed | Meals · 2025-12-19 | None | $123 |
| Pfizer | Meals · 2025-12-08 | Vyndaqel | $31 |
| Baxter Healthcare | Meals · 2025-11-25 | Hillrom - Carnation Ambulatory Monitor | $21 |
| Baxter Healthcare | Meals · 2025-11-14 | Hillrom - Carnation Ambulatory Monitor | $23 |
| Novartis Pharmaceuticals | Meals · 2025-10-16 | Leqvio | $27 |
| Paragonix Technologies | Meals · 2025-10-01 | Sherpapak | $44 |
| Alnylam Pharmaceuticals | Meals · 2025-05-29 | Onpattro | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-11 | None | $26 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $479
| Abbott Laboratories | Thoratec Heartmate 3 Lvas Implant Kit | $183 | 3 payments
|
| Impulse Dynamics (USA) | Optimizer | $129 | 1 payment
|
| iRhythm Technologies | Zio Monitor | $44 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $42 | 1 payment
|
| CVRx | Barostim Neo System | $32 | 1 payment
|
| One Lambda | None | $29 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $21 | 1 payment
|
2023: $54
| Abbott Laboratories | Thoratec Heartmate 3 Lvas Implant Kit | $54 | 2 payments
|
2022: $75
| Abbott Laboratories | Thoratec Heartmate 3 Lvas Implant Kit | $75 | 2 payments
|
2021: $340
| Abbott Laboratories | Heartmate 3 Left Ventricular Assist Device | $143 | 3 payments
|
| Novartis Pharmaceuticals | Leqvio | $65 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $48 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $45 | 3 payments
|
| HeartFlow | Ffrct | $21 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $18 | 1 payment
|
2020: $359
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $121 | 3 payments
|
| Amgen | Repatha | $94 | 4 payments
|
| Abbott Laboratories | Heartmate 3 Left Ventricular Dev | $45 | 2 payments
|
| CathWorks | Ffrangio System | $26 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $25 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $16 | 1 payment
|
| iRhythm Technologies | Zio Patch | $16 | 1 payment
|
| Pfizer | Eliquis | $15 | 1 payment
|
2019: $1,068
| Novartis Pharmaceuticals | Entresto | $358 | 4 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $202 | 4 payments
|
| Amgen | Repatha | $150 | 5 payments
|
| Abbott Laboratories | Heartmate | $113 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $70 | 4 payments
|
| Lundbeck | Northera | $43 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $39 | 3 payments
|
| Regeneron Healthcare Solutions | Praluent | $31 | 1 payment
|
| HeartFlow | None | $24 | 2 payments
|
| Boston Scientific | Watchman | $22 | 1 payment
|
| iRhythm Technologies | Zio Patch | $15 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · Prospective Comparison of Arni With Arb Given Following Stabilization in Decompensated Hfpef (Paraglide-Hfpef) · 2022 | Their institution | $95,384 |
| Novartis Pharmaceuticals Corporation · Prospective Comparison of Arni With Arb Given Following Stabilization in Decompensated Hfpef (Paraglide-Hfpef) · 2021 | Their institution | $86,974 |
| Novartis Pharmaceuticals Corporation · Prospective Comparison of Arni With Arb Given Following Stabilization in Decompensated Hfpef (Paraglide-Hfpef) · 2020 | Their institution | $22,438 |
| Novartis Pharmaceuticals Corporation · Prospective Comparison of Arni With Arb Given Following Stabilization in Decompensated Hfpef (Paraglide-Hfpef) · 2023 | Their institution | $8,828 |
Professional record
- NPI
- 1033376017
- Licence
- CA A108532, MA 228223California A108532: Current · expires 2027-06-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RA0001X (207RA0001X); Internal medicine (207R00000X); Cardiology (207RC0000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2008-05-19
- NPI last updated
- 2020-05-29
- NPI record certified
- 2020-05-29
This is when the NPI record was last certified, not a medical board exam.